Delivery Order SPE2DB24D2205-SPE2DB25FEFUU
- Not listed
- The Defense Logistics Agency awarded a $8,222.46 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 15, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $7,046.76 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,819.92 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes on August 27, 2025, with completion scheduled for August 28, 2025. This non-competitive, firm fixed-price delivery order represents a single procurement under AmerisourceBergen's larger contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, which serves as...
- The Defense Logistics Agency awarded a $2,194.02 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX),...
- The Defense Logistics Agency awarded a $38,034.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract, which is not set-aside and was competitively awarded, requires completion by June 18, 2025, with performance to be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,013.11 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract is a firm fixed-price delivery order with a completion date of August 6, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability to compete for federal medical...
- The Defense Logistics Agency awarded a $7,062.93 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This competitive award, which is non-set-aside, will be performed at the contractor's Conshohocken, Pennsylvania location with an ultimate completion date of July 15, 2025. The contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $9,019.91 to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award to a qualified vendor. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This delivery order...
- The Defense Logistics Agency awarded a $9,521.32 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL units). This firm fixed-price contract, which must be completed by September 10, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively procured without set-aside restrictions, reflecting the contractor's established capability to...
- The Defense Logistics Agency awarded a delivery order valued at $6,708.32 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes on July 24, 2025, with completion expected by July 25, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFUUDelivery Order
The Defense Logistics Agency awarded a $8,874.09 delivery order to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. This contract employs firm fixed pricing and carries no set-aside designation, indicating it was awarded through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The supply of Monovisc, a hyaluronic acid-based injectable used for osteoarthritis treatment, supports the Defense Health Agency's pharmaceutical supply requirements for military healthcare programs. AmerisourceBergen, as a major pharmaceutical distributor and critical vendor for federal medical procurement, maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's comprehensive IDC vehicle enables flexible fulfillment of pharmaceutical needs across the military healthcare system globally, with DLA planning future Pharmaceutical Prime Vendor Global Program Generation V contracts potentially involving multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| No Federal Contract Transactions match your search | ||||